 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Biopharmaceutics, Inc. is a small company that shot itself in the foot about a year ago. The FDA hammered them pretty good and then Avon took them to the woodshed in a court case involving a product ownership dispute. Since then BOPH has shelved their research for the time being and has concentrated on renewing their generic drug production and distribution. They also purchased a line of feminine hygeine products as a new area of diversification. They are currently looking for another aquisition because the hygeine line has been so promising. On July 11 BOPH announced 3rd qtr. sales had increased to $1,150,000 compared to $194,000 in 95. Earnings report will be out around July 22, with a small earning anticipated compared to $500,000 loss the year before. With sales of feminine hygeine products increasing and the generic drug manufacturing back on track for profitability, BOPH will have the capital to make another aquisition and may, in time, have the capital to renew research on the patents they hold. BOPH has traded between .30 and .40 for several months. If they begin to show earnings it will be the end of a long tunnel of coporate mistakes and bad luck, and the beginning of new profitability. I would like to hear comments from others who own this company. Any responses out there? | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |